Score Overview
Explore the 2021 public Archive ranking →
Where Bristol-Myers Squibb Company has ranked, year by year
Showing 30 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- BMY
2018: 82.1% · 2021: 85.0% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 63.88 | — |
1 Year2025-09-26 | $ 42.10 | 51.74% |
5 Years2021-09-28 | $ 48.76 | 31.01% |
10 Years2016-09-28 | $ 38.73 | 64.93% |
20 Years2006-09-28 | $ 11.70 | 446.12% |
30 Years1996-09-27 | $ 7.75 | 8x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 63.88 | $ 42.10 | $ 48.76 | $ 38.73 | $ 11.70 | $ 7.75 |
| Return | — | 51.74% | 31.01% | 64.93% | 446.12% | 8x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 49.18B | $ 9.28B | $ 11.06B |
| 2025 | $ 48.19B | $ 7.05B | $ 10.67B |
| 2024 | $ 48.30B | -$ 8.94B | $ 10.85B |
| 2023 | $ 45.00B | $ 8.02B | $ 12.28B |
| 2022 | $ 46.15B | $ 6.32B | $ 9.25B |
| 2021 | $ 46.38B | $ 6.99B | $ 17.22B |
| 2020 | $ 42.51B | -$ 8.99B | $ 16.45B |
| 2019 | $ 26.14B | $ 3.43B | $ 15.39B |
| 2018 | $ 22.56B | $ 4.92B | $ 8.75B |
| 2017 | $ 20.77B | $ 1.00B | $ 6.81B |
| 2016 | $ 19.42B | $ 4.45B | $ 6.35B |
| 2015 | $ 16.56B | $ 1.56B | $ 4.27B |
| 2014 | $ 15.87B | $ 2.00B | $ 7.43B |
| 2013 | $ 16.38B | $ 2.56B | $ 4.52B |
| 2012 | $ 17.62B | $ 1.96B | $ 2.82B |
| 2011 | $ 21.24B | $ 3.70B | $ 8.73B |
| 2010 | $ 19.48B | $ 3.10B | $ 7.30B |
| 2009 | $ 18.80B | $ 10.61B | $ 8.51B |
| 2008 | $ 20.59B | $ 5.24B | $ 8.26B |
| 2007 | $ 19.34B | $ 2.16B | $ 2.22B |
| 2006 | $ 17.91B | $ 1.58B | $ 4.01B |
| 2005 | $ 19.20B | $ 3.00B | $ 5.79B |
| 2004 | $ 19.38B | $ 2.38B | $ 7.47B |
| 2003 | $ 20.89B | $ 3.10B | $ 5.56B |
| 2002 | $ 18.11B | $ 2.13B | $ 3.98B |
| 2001 | $ 19.42B | $ 5.24B | $ 5.65B |
| 2000 | $ 18.21B | $ 4.71B | $ 3.38B |
| 1999 | $ 20.22B | $ 4.16B | $ 2.95B |
| 1998 | $ 18.28B | $ 3.14B | $ 2.24B |
| 1997 | $ 16.70B | $ 3.20B | $ 1.45B |
| 1996 | $ 15.06B | $ 2.85B | $ 1.68B |
| 1995 | $ 13.76B | $ 1.81B | $ 1.64B |
| 1994 | $ 11.98B | $ 1.84B | $ 1.64B |
| 1993 | $ 11.41B | $ 1.95B | $ 2.42B |
| 1992 | $ 11.15B | $ 1.96B | $ 2.13B |
| 1991 | $ 11.15B | $ 2.05B | $ 1.43B |
| 1990 | $ 10.30B | $ 1.74B | $ 596M |
| 1989 | $ 9.18B | $ 747M | $ 510M |
| 1988 | $ 8.55B | $ 1.25B | $ 2.51B |
| 1987 | $ 7.55B | $ 1.06B | $ 2.34B |
Bristol-Myers Squibb Company fundamental performance
Between 2020 and 2025, revenue grew from $ 42.51B to $ 48.19B and net income went from -$ 8.99B to $ 7.05B. Revenue increased in 2 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 16.56B to $ 48.19B and net income grew from $ 1.56B to $ 7.05B. Revenue increased in 7 of those 10 years; net income in 5.
Bristol-Myers Squibb Company currently holds a 20-year HDB Score of 5.4 out of 10. How the HDB Score is calculated.
Membership
Continue BMY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
